Sorafenib as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC)- a Pilot Trial to Evaluate Safety and Biological Response

Trial Profile

Sorafenib as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC)- a Pilot Trial to Evaluate Safety and Biological Response

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2015

At a glance

  • Drugs Sorafenib (Primary) ; Doxorubicin; Ethiodized oil
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Soratace-1
  • Most Recent Events

    • 15 Mar 2012 Actual end date changed from Nov 2010 to Mar 2011 as reported by European Clinical Trials Database.
    • 15 Mar 2012 Actual initiation date changed from Sep 2008 to Mar 2008 as reported by European Clinical Trials Database.
    • 08 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top